Business Context and Reporting Period
Company: Revelation Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 13, 2022
Date of Earliest Event: January 11, 2022
Reporting Period: This filing reports a specific event occurring on January 11, 2022, rather than a standard financial reporting period.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to disclose the release of an investor presentation.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The sole material event is the public posting of an investor presentation on the company's website.
Guidance, Outlook, and Management Commentary
Regulation FD Disclosure: On January 11, 2022, the company posted an investor presentation on its website (www.revbiosciences.com).
Legal Status of Information: The information contained in the presentation (Exhibit 99.1) is furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act. It is not subject to the liabilities of that section and shall not be incorporated by reference into any Securities Act or Exchange Act filings.
Securities Registered: The company lists Units (REVBU), Common Stock (REVB), and Redeemable Warrants (REVBW) trading on The Nasdaq Stock Market LLC.
Investor Verification Checklist
- Verify the content of the "Investor Presentation January 2022" (Exhibit 99.1) posted on the company website, as this filing only references its existence.
- Confirm the trading status and exercise price ($11.50) of the redeemable warrants (REVBW) on Nasdaq.
- Note that the information in the presentation is not incorporated by reference into this 8-K filing.
- Check for subsequent filings for actual financial performance data, as this 8-K contains no financial metrics.